Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma
NCT07099430Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in melanoma, sponsored by Leads Biolabs. Started Sep 2025; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07099430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099430.